Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91


Intratumoral delivery of an HPV vaccine elicits a broad anti-tumor immune response that translates into a potent anti-tumor effect in a preclinical murine HPV model.

Ishida E, Lee J, Campbell JS, Chakravarty PD, Katori Y, Ogawa T, Johnson L, Mukhopadhyay A, Faquin WC, Lin DT, Wirth LJ, Pierce RH, Pai SI.

Cancer Immunol Immunother. 2019 Aug;68(8):1273-1286. doi: 10.1007/s00262-019-02357-1. Epub 2019 Jun 26.


Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040).

Pai SI, Faivre S, Licitra L, Machiels JP, Vermorken JB, Bruzzi P, Gruenwald V, Giglio RE, Leemans CR, Seiwert TY, Soulieres D.

J Immunother Cancer. 2019 Apr 3;7(1):96. doi: 10.1186/s40425-019-0578-0.


Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications.

Wolkow N, Jakobiec FA, Afrogheh AH, Eagle RC Jr, Pai SI, Faquin WC.

Am J Ophthalmol. 2019 Apr;200:226-241. doi: 10.1016/j.ajo.2018.12.020. Epub 2019 Jan 8.


Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.

Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M, Gungabeesoon J, Freeman GJ, Warren SE, Ong S, Browning E, Twitty CG, Pierce RH, Le MH, Algazi AP, Daud AI, Pai SI, Zippelius A, Weissleder R, Pittet MJ.

Immunity. 2018 Dec 18;49(6):1148-1161.e7. doi: 10.1016/j.immuni.2018.09.024. Epub 2018 Dec 11.


Functional and genomic analyses reveal therapeutic potential of targeting β-catenin/CBP activity in head and neck cancer.

Kartha VK, Alamoud KA, Sadykov K, Nguyen BC, Laroche F, Feng H, Lee J, Pai SI, Varelas X, Egloff AM, Snyder-Cappione JE, Belkina AC, Bais MV, Monti S, Kukuruzinska MA.

Genome Med. 2018 Jul 20;10(1):54. doi: 10.1186/s13073-018-0569-7.


PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma.

Rosenbaum MW, Gigliotti BJ, Pai SI, Parangi S, Wachtel H, Mino-Kenudson M, Gunda V, Faquin WC.

Endocr Pathol. 2018 Mar;29(1):59-67. doi: 10.1007/s12022-018-9514-y.


HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers.

Pai SI, Jack Lee J, Carey TE, Westra WH, Ferrone S, Moore C, Mosunjac MB, Shin DM, Ferris RL; HNC SPORE HIV supplement consortium.

Oral Oncol. 2018 Feb;77:92-97. doi: 10.1016/j.oraloncology.2017.12.014. Epub 2017 Dec 28.


Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.

Gleber-Netto FO, Zhao M, Trivedi S, Wang J, Jasser S, McDowell C, Kadara H, Zhang J, Wang J, William WN Jr, Lee JJ, Nguyen ML, Pai SI, Walline HM, Shin DM, Ferris RL, Carey TE, Myers JN, Pickering CR; Head and Neck Cancer Specialized Program of Research Excellence (SPORE) Human Immunodeficiency Virus (HIV) Supplement Consortium.

Cancer. 2018 Jan 1;124(1):84-94. doi: 10.1002/cncr.31063. Epub 2017 Oct 20.


PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4+ TILs in the Presence of PD-L1+ TAMs.

Mattox AK, Lee J, Westra WH, Pierce RH, Ghossein R, Faquin WC, Diefenbach TJ, Morris LG, Lin DT, Wirth LJ, Lefranc-Torres A, Ishida E, Chakravarty PD, Johnson L, Zeng YC, Chen H, Poznansky MC, Iyengar NM, Pai SI.

Cancer Res. 2017 Nov 15;77(22):6365-6374. doi: 10.1158/0008-5472.CAN-16-3453. Epub 2017 Sep 25.


Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma.

Zhang H, Kim S, Chen Z, Nannapaneni S, Chen AY, Moore CE, Sica G, Mosunjac M, Nguyen MLT, D'Souza G, Carey TE, Peterson LA, McHugh JB, Graham M, Komarck CM, Wolf GT, Walline HM, Bellile E, Riddell J 4th, Pai SI, Sidransky D, Westra WH, William WN Jr, Lee JJ, El-Naggar AK, Ferris RL, Seethala R, Grandis JR, Chen ZG, Saba NF, Shin DM; Head and Neck Cancer SPORE HIV supplement consortium.

Head Neck. 2017 Dec;39(12):2433-2443. doi: 10.1002/hed.24911. Epub 2017 Sep 25.


Programmed cell death ligand 1 as a biomarker in head and neck cancer.

Pai SI, Faquin WC.

Cancer Cytopathol. 2017 Jul;125(7):529-533. doi: 10.1002/cncy.21872. Epub 2017 May 4. No abstract available.


Adjuvant radiotherapy is not supported in patients with verrucous carcinoma of the oral cavity.

Mohan S, Pai SI, Bhattacharyya N.

Laryngoscope. 2017 Jun;127(6):1334-1338. doi: 10.1002/lary.26443. Epub 2017 Feb 1.


High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV.

Walline HM, Carey TE, Goudsmit CM, Bellile EL, D'Souza G, Peterson LA, McHugh JB, Pai SI, Lee JJ, Shin DM, Ferris RL; HNC SPORE HIV supplement consortium.

Mol Cancer Res. 2017 Feb;15(2):179-188. doi: 10.1158/1541-7786.MCR-16-0255. Epub 2016 Nov 29.


The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment.

Pai SI, Zandberg DP, Strome SE.

Oral Oncol. 2016 Oct;61:152-8. doi: 10.1016/j.oraloncology.2016.08.001. Epub 2016 Aug 5. Review.


Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines.

Brotherton JM, Jit M, Gravitt PE, Brisson M, Kreimer AR, Pai SI, Fakhry C, Monsonego J, Franceschi S.

Int J Cancer. 2016 Aug 1;139(3):510-7. doi: 10.1002/ijc.30063. Epub 2016 Mar 22. Review.


Identification of the murine H-2D(b) and human HLA-A*0201 MHC class I-restricted HPV6 E7-specific cytotoxic T lymphocyte epitopes.

Peng S, Mattox A, Best SR, Barbu AM, Burns JA, Akpeng B, Jeang J, Yang B, Ishida E, Hung CF, Wu TC, Pai SI.

Cancer Immunol Immunother. 2016 Mar;65(3):261-71. doi: 10.1007/s00262-016-1793-x. Epub 2016 Jan 13.


Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study.

Anderson KS, Gerber JE, D'Souza G, Pai SI, Cheng JN, Alam R, Kesiraju S, Chowell D, Gross ND, Haddad R, Gillison ML, Posner M.

Oral Oncol. 2015 Aug;51(8):751-8. doi: 10.1016/j.oraloncology.2015.05.007. Epub 2015 Jun 18.


In-situ tumor vaccination: Bringing the fight to the tumor.

Pierce RH, Campbell JS, Pai SI, Brody JD, Kohrt HE.

Hum Vaccin Immunother. 2015;11(8):1901-9. doi: 10.1080/21645515.2015.1049779. Review.


Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer.

Peng S, Wang JW, Karanam B, Wang C, Huh WK, Alvarez RD, Pai SI, Hung CF, Wu TC, Roden RB.

PLoS One. 2015 Jan 5;10(1):e116389. doi: 10.1371/journal.pone.0116389. eCollection 2015.


Xenograft model for therapeutic drug testing in recurrent respiratory papillomatosis.

Ahn J, Bishop JA, Akpeng B, Pai SI, Best SR.

Ann Otol Rhinol Laryngol. 2015 Feb;124(2):110-5. doi: 10.1177/0003489414546400. Epub 2014 Aug 13.


A staged thyroidectomy approach for gastric bypass patients.

Gooi Z, Ward BK, Mener DJ, Ozgursoy OB, Pai SI.

Laryngoscope. 2015 Apr;125(4):1028-30. doi: 10.1002/lary.24835. Epub 2014 Jul 18. No abstract available.


PET/CT in the management of thyroid cancers.

Marcus C, Whitworth PW, Surasi DS, Pai SI, Subramaniam RM.

AJR Am J Roentgenol. 2014 Jun;202(6):1316-29. doi: 10.2214/AJR.13.11673. Review.


Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners.

D'Souza G, Gross ND, Pai SI, Haddad R, Anderson KS, Rajan S, Gerber J, Gillison ML, Posner MR.

J Clin Oncol. 2014 Aug 10;32(23):2408-15. doi: 10.1200/JCO.2014.55.1341. Epub 2014 Apr 28.


Human papillomavirus status of head and neck cancer as determined in cytologic specimens using the hybrid-capture 2 assay.

Smith DF, Maleki Z, Coughlan D, Gooi Z, Akpeng B, Ogawa T, Bishop JA, Frick KD, Agrawal N, Gourin CG, Ha PK, Koch WM, Richmon JD, Westra WH, Pai SI.

Oral Oncol. 2014 Jun;50(6):600-4. doi: 10.1016/j.oraloncology.2014.02.011. Epub 2014 Mar 12.


The impact of molecular testing on the surgical management of patients with thyroid nodules.

Aragon Han P, Olson MT, Fazeli R, Prescott JD, Pai SI, Schneider EB, Tufano RP, Zeiger MA.

Ann Surg Oncol. 2014 Jun;21(6):1862-9. doi: 10.1245/s10434-014-3508-x. Epub 2014 Feb 13.


Epidemiology of head and neck squamous cell cancer among HIV-infected patients.

Dʼsouza G, Carey TE, William WN Jr, Nguyen ML, Ko EC, Riddell J 4th, Pai SI, Gupta V, Walline HM, Lee JJ, Wolf GT, Shin DM, Grandis JR, Ferris RL.

J Acquir Immune Defic Syndr. 2014 Apr 15;65(5):603-10. doi: 10.1097/QAI.0000000000000083.


Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors.

Wu CY, Yang LH, Yang HY, Knoff J, Peng S, Lin YH, Wang C, Alvarez RD, Pai SI, Roden RB, Hung CF, Wu TC.

Clin Cancer Res. 2014 Feb 1;20(3):644-57. doi: 10.1158/1078-0432.CCR-13-1334. Epub 2013 Dec 3.


The relationship between chronic lymphocytic thyroiditis and central neck lymph node metastasis in North American patients with papillary thyroid carcinoma.

Jara SM, Carson KA, Pai SI, Agrawal N, Richmon JD, Prescott JD, Dackiw A, Zeiger MA, Bishop JA, Tufano RP.

Surgery. 2013 Dec;154(6):1272-80; discussion 1280-2. doi: 10.1016/j.surg.2013.07.021.


Long-term prognosis and risk factors among patients with HPV-associated oropharyngeal squamous cell carcinoma.

Lin BM, Wang H, D'Souza G, Zhang Z, Fakhry C, Joseph AW, Drake VE, Sanguineti G, Westra WH, Pai SI.

Cancer. 2013 Oct 1;119(19):3462-71. doi: 10.1002/cncr.28250. Epub 2013 Jul 16.


Mission impossible: how HPV-associated head and neck cancers escape a primed immune response.

Pai SI.

Oral Oncol. 2013 Aug;49(8):723-5. doi: 10.1016/j.oraloncology.2013.03.453. Epub 2013 May 1. No abstract available.


Human papillomavirus-related carcinoma with adenoid cystic-like features: a peculiar variant of head and neck cancer restricted to the sinonasal tract.

Bishop JA, Ogawa T, Stelow EB, Moskaluk CA, Koch WM, Pai SI, Westra WH.

Am J Surg Pathol. 2013 Jun;37(6):836-44. doi: 10.1097/PAS.0b013e31827b1cd6.


Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.

Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Tufano RP, Pai SI, Zeiger MA, Westra WH, Clark DP, Clifton-Bligh R, Sidransky D, Ladenson PW, Sykorova V.

JAMA. 2013 Apr 10;309(14):1493-501. doi: 10.1001/jama.2013.3190.


Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma.

Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, Bruno TC, Richmon JD, Wang H, Bishop JA, Chen L, Drake CG, Topalian SL, Pardoll DM, Pai SI.

Cancer Res. 2013 Mar 15;73(6):1733-41. doi: 10.1158/0008-5472.CAN-12-2384. Epub 2013 Jan 3.


Human papillomavirus-related carcinomas of the sinonasal tract.

Bishop JA, Guo TW, Smith DF, Wang H, Ogawa T, Pai SI, Westra WH.

Am J Surg Pathol. 2013 Feb;37(2):185-92. doi: 10.1097/PAS.0b013e3182698673.


Molecular etiology of second primary tumors in contralateral tonsils of human papillomavirus-associated index tonsillar carcinomas.

Joseph AW, Ogawa T, Bishop JA, Lyford-Pike S, Chang X, Phelps TH, Westra WH, Pai SI.

Oral Oncol. 2013 Mar;49(3):244-8. doi: 10.1016/j.oraloncology.2012.09.009. Epub 2012 Oct 10.


Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine.

Peng S, Lyford-Pike S, Akpeng B, Wu A, Hung CF, Hannaman D, Saunders JR, Wu TC, Pai SI.

Cancer Immunol Immunother. 2013 Jan;62(1):171-82. doi: 10.1007/s00262-012-1322-5. Epub 2012 Aug 4.


HPV-associated head and neck cancers.

Pai SI.

Otolaryngol Clin North Am. 2012 Aug;45(4):xi-xii. doi: 10.1016/j.otc.2012.05.003. Epub 2012 May 16. No abstract available.


Biology of human papillomavirus infection and immune therapy for HPV-related head and neck cancers.

Best SR, Niparko KJ, Pai SI.

Otolaryngol Clin North Am. 2012 Aug;45(4):807-22. doi: 10.1016/j.otc.2012.04.005. Review.


Hyperfractionated radiotherapy with concurrent cisplatin/5-Fluorouracil for locoregional advanced head and neck cancer: analysis of 105 consecutive patients.

Zaboli D, Tan M, Gogineni H, Lake S, Fan K, Zahurak ML, Messing B, Ulmer K, Zinreich ES, Levine MA, Tang M, Pai SI, Blanco RG, Saunders JR, Best SR, Califano JA, Ha PK.

Int J Otolaryngol. 2012;2012:754191. doi: 10.1155/2012/754191. Epub 2012 Jun 21.


Comparison of acute toxicities in two primary chemoradiation regimens in the treatment of advanced head and neck squamous cell carcinoma.

Fan KY, Gogineni H, Zaboli D, Lake S, Zahurak ML, Best SR, Levine MA, Tang M, Zinreich ES, Saunders JR, Califano JA, Blanco RG, Pai SI, Messing B, Ha PK.

Ann Surg Oncol. 2012 Jun;19(6):1980-7. doi: 10.1245/s10434-012-2219-4.


HPV analysis in distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma.

Bishop JA, Ogawa T, Chang X, Illei PB, Gabrielson E, Pai SI, Westra WH.

Am J Surg Pathol. 2012 Jan;36(1):142-8. doi: 10.1097/PAS.0b013e3182395c7b.


Incidence of malignancy in thyroid nodules determined to be follicular lesions of undetermined significance on fine-needle aspiration.

Teixeira GV, Chikota H, Teixeira T, Manfro G, Pai SI, Tufano RP.

World J Surg. 2012 Jan;36(1):69-74. doi: 10.1007/s00268-011-1336-8.


Determining the extent of lateral neck dissection necessary to establish regional disease control and avoid reoperation after previous total thyroidectomy and radioactive iodine for papillary thyroid cancer.

Wu G, Fraser S, Pai SI, Farrag TY, Ladenson PW, Tufano RP.

Head Neck. 2012 Oct;34(10):1418-21. doi: 10.1002/hed.21937. Epub 2011 Nov 3.


Profile of patients with completion thyroidectomy and assessment of their suitability for outpatient surgery.

Wu G, Pai SI, Agrawal N, Richmon J, Dackiw A, Tufano RP.

Otolaryngol Head Neck Surg. 2011 Nov;145(5):727-31. doi: 10.1177/0194599811416749. Epub 2011 Aug 22.


Application of the hybrid capture 2 assay to squamous cell carcinomas of the head and neck: a convenient liquid-phase approach for the reliable determination of human papillomavirus status.

Bishop JA, Maleki Z, Valsamakis A, Ogawa T, Chang X, Pai SI, Westra WH.

Cancer Cytopathol. 2012 Feb 25;120(1):18-25. doi: 10.1002/cncy.20175. Epub 2011 Jul 12.


Tumor size and presence of calcifications on ultrasonography are pre-operative predictors of lymph node metastases in patients with papillary thyroid cancer.

Gomez NR, Kouniavsky G, Tsai HL, Somervell H, Pai SI, Tufano RP, Umbricht C, Kowalski J, Dackiw AP, Zeiger MA.

J Surg Oncol. 2011 Nov 1;104(6):613-6. doi: 10.1002/jso.21891. Epub 2011 Jul 8.


Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer.

Anderson KS, Wong J, D'Souza G, Riemer AB, Lorch J, Haddad R, Pai SI, Longtine J, McClean M, LaBaer J, Kelsey KT, Posner M.

Br J Cancer. 2011 Jun 7;104(12):1896-905. doi: 10.1038/bjc.2011.171.


Promoter methylation of leukemia inhibitory factor receptor gene in colorectal carcinoma.

Cho YG, Chang X, Park IS, Yamashita K, Shao C, Ha PK, Pai SI, Sidransky D, Kim MS.

Int J Oncol. 2011 Aug;39(2):337-44. doi: 10.3892/ijo.2011.1050. Epub 2011 May 23.


Characterization of the methylation patterns in human papillomavirus type 16 viral DNA in head and neck cancers.

Park IS, Chang X, Loyo M, Wu G, Chuang A, Kim MS, Chae YK, Lyford-Pike S, Westra WH, Saunders JR, Sidransky D, Pai SI.

Cancer Prev Res (Phila). 2011 Feb;4(2):207-17. doi: 10.1158/1940-6207.CAPR-10-0147.

Supplemental Content

Support Center